United States securities and exchange commission logo

                            June 9, 2021

       Julien Gander, LL.M.
       General Counsel
       Molecular Partners AG
       Wagistrasse 14
       8952 Z  rich-Schlieren

                                                        Re: Molecular Partners
                                                            Amendment No. 3 to
Registration Statement on Form F-1
                                                            Filed June 9, 2021
                                                            File No. 333-255447

       Dear Mr. Gander:

             We have reviewed your amended registration statement and have the
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 3 to Registration Statement on Form F-1

       Use of Proceeds, page 83

   1.                                                   We note your disclosure
that you intend to advance the development of your infectious
                                                        disease program
including the expansion of your research and development activities for
                                                        COVID-19 antiviral
therapeutic product candidates using the proceeds of this offering.
                                                        Please revise to
disclose an estimate of how far in the development of your infectious
                                                        disease program the
proceeds from this offering will allow you to reach, including
                                                        the development of a
certain number of additional products, specific phases of clinical
                                                        trials or preclinical
 Julien Gander, LL.M.
Molecular Partners AG
June 9, 2021
Page 2
Swiss Tax Implications for U.S. Holders, page 234

2.    We note that the tax opinion filed as Exhibit 8.1 appears to be a
short-form tax opinion.
      Please revise this section in your filing to clearly identify that the
"Swiss Tax Implications
      for U.S. Holders" disclosure is the opinion of the counsel or accountant.
Please revise the
      opinion to also include a similar statement. Counsel or the accountant
must opine on the
      tax consequences of the offering, not the manner in which those
consequences are
      described in the prospectus. For guidance, refer to Sections III.B.2 and
III.C.2 of Staff
      Legal Bulletin No. 19.
       You may contact Christie Wong at 202-551-3684 or Terence O'Brien at
202-551-3355 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Ada D. Sarmento at 202-551-3798 or Tim Buchmiller at 202-551-3635 with
any other

FirstName LastNameJulien Gander, LL.M.
                                                             Division of
Corporation Finance
Comapany NameMolecular Partners AG
                                                             Office of Life
June 9, 2021 Page 2
cc:       Ryan Sansom, Esq.
FirstName LastName